These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8946671)

  • 1. Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents.
    Boudoulas S; Lush RM; McCall NA; Samid D; Reed E; Figg WD
    Ther Drug Monit; 1996 Dec; 18(6):714-20. PubMed ID: 8946671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate.
    Berg S; Serabe B; Aleksic A; Bomgaars L; McGuffey L; Dauser R; Durfee J; Nuchtern J; Blaney S
    Cancer Chemother Pharmacol; 2001 May; 47(5):385-90. PubMed ID: 11391852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine.
    Piscitelli SC; Thibault A; Figg WD; Tompkins A; Headlee D; Lieberman R; Samid D; Myers CE
    J Clin Pharmacol; 1995 Apr; 35(4):368-73. PubMed ID: 7650225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers.
    Samid D; Hudgins WR; Shack S; Liu L; Prasanna P; Myers CE
    Adv Exp Med Biol; 1997; 400A():501-5. PubMed ID: 9547596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of phenylbutyrate metabolites by UPLC-MS/MS demonstrates inverse correlation of phenylacetate:phenylacetylglutamine ratio with plasma glutamine levels.
    Jiang Y; Almannai M; Sutton VR; Sun Q; Elsea SH
    Mol Genet Metab; 2017 Nov; 122(3):39-45. PubMed ID: 28888854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate.
    Liu L; Shack S; Stetler-Stevenson WG; Hudgins WR; Samid D
    J Invest Dermatol; 1994 Sep; 103(3):335-40. PubMed ID: 8077698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
    Carducci MA; Gilbert J; Bowling MK; Noe D; Eisenberger MA; Sinibaldi V; Zabelina Y; Chen TL; Grochow LB; Donehower RC
    Clin Cancer Res; 2001 Oct; 7(10):3047-55. PubMed ID: 11595694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate.
    Miller AC; Whittaker T; Thibault A; Samid D
    Int J Radiat Biol; 1997 Aug; 72(2):211-8. PubMed ID: 9269314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
    Mokhtarani M; Diaz GA; Rhead W; Lichter-Konecki U; Bartley J; Feigenbaum A; Longo N; Berquist W; Berry SA; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Bart S; Kronn D; Zori R; Cederbaum S; Dorrani N; Merritt JL; Sreenath-Nagamani S; Summar M; Lemons C; Dickinson K; Coakley DF; Moors TL; Lee B; Scharschmidt BF
    Mol Genet Metab; 2012 Nov; 107(3):308-14. PubMed ID: 22958974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional upregulation of TGF-alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells.
    Liu L; Hudgins WR; Miller AC; Chen LC; Samid D
    Cytokine; 1995 Jul; 7(5):449-56. PubMed ID: 7578983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity.
    Samid D; Wells M; Greene ME; Shen W; Palmer CN; Thibault A
    Clin Cancer Res; 2000 Mar; 6(3):933-41. PubMed ID: 10741718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate.
    Shack S; Miller A; Liu L; Prasanna P; Thibault A; Samid D
    Clin Cancer Res; 1996 May; 2(5):865-72. PubMed ID: 9816242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification.
    Cosentini E; Haberl I; Pertschy P; Teleky B; Mallinger R; Baumgartner G; Wenzl E; Hamilton G
    Int J Oncol; 2001 Nov; 19(5):1069-74. PubMed ID: 11605011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Mokhtarani M; Diaz GA; Rhead W; Berry SA; Lichter-Konecki U; Feigenbaum A; Schulze A; Longo N; Bartley J; Berquist W; Gallagher R; Smith W; McCandless SE; Harding C; Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Dickinson K; Moors T; Norris C; Coakley D; Milikien DA; Nagamani SC; Lemons C; Lee B; Scharschmidt BF
    Mol Genet Metab; 2013 Dec; 110(4):446-53. PubMed ID: 24144944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans.
    Comte B; Kasumov T; Pierce BA; Puchowicz MA; Scott ME; Dahms W; Kerr D; Nissim I; Brunengraber H
    J Mass Spectrom; 2002 Jun; 37(6):581-90. PubMed ID: 12112740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities.
    Newmark HL; Young CW
    J Cell Biochem Suppl; 1995; 22():247-53. PubMed ID: 8538206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible Phenylacetate Hepatotoxicity During 4-Phenylbutyrate Therapy of Byler Disease.
    Shneider BL; Morris A; Vockley J
    J Pediatr Gastroenterol Nutr; 2016 Mar; 62(3):424-8. PubMed ID: 26756876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
    Lee B; Rhead W; Diaz GA; Scharschmidt BF; Mian A; Shchelochkov O; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Gargosky S; Mokhtarani M; Berry SA
    Mol Genet Metab; 2010 Jul; 100(3):221-8. PubMed ID: 20382058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion.
    Brusilow SW
    Pediatr Res; 1991 Feb; 29(2):147-50. PubMed ID: 2014149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of girls with ornithine transcarbamylase deficiency.
    Maestri NE; Brusilow SW; Clissold DB; Bassett SS
    N Engl J Med; 1996 Sep; 335(12):855-9. PubMed ID: 8778603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.